Axogen/$AXGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
- Ticker
- $AXGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 622
- Headquarters
- Alachua, United States
- Website
- www.axogeninc.com
Axogen Metrics
BasicAdvanced
$3.3B
-
-$0.62
1.17
-
Price and volume
Market cap
$3.3B
Beta
1.17
52-week high
$59.72
52-week low
$23.00
Average daily volume
2M
Financial strength
Current ratio
12.017
Quick ratio
10.48
Long term debt to equity
0.036
Total debt to equity
0.039
Interest coverage (TTM)
-5.72%
Profitability
EBITDA (TTM)
-6.962
Gross margin (TTM)
74.18%
Net profit margin (TTM)
-11.96%
Operating margin (TTM)
-5.17%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-2.25%
Return on equity (TTM)
-10.35%
Valuation
Price to revenue (TTM)
10.73
Price to book
6.67
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
143.051
Free cash flow yield (TTM)
0.70%
Free cash flow per share (TTM)
0.387
Growth
Revenue change (TTM)
24.32%
Earnings per share change (TTM)
1,160.77%
3-year revenue growth (CAGR)
20.58%
10-year revenue growth (CAGR)
21.68%
3-year earnings per share growth (CAGR)
3.91%
10-year earnings per share growth (CAGR)
4.12%
What the Analysts think about Axogen
Analyst ratings (Buy, Hold, Sell) for Axogen stock.
Analyst projections of the future price of Axogen stock.
Bulls say / Bears say
Third-quarter revenue rose 26.2% year on year, and Axogen raised its 2026 revenue outlook to at least $290 million, or 29% growth. It also reported quarterly net income and expects positive free cash flow for the full year. (Axogen)
Coverage decisions from Elevance and Aetna have lifted Avance coverage to about 96% of covered US lives. Wider insurance access could make it easier for surgeons and hospitals to adopt the product. (Axogen)
The BioCircuit acquisition adds NerveTape, a sutureless repair product that could broaden Axogen’s reach to surgeons who do not routinely use microsutures. Axogen expects the deal to add to revenue growth, adjusted EBITDA margin and adjusted earnings per share in its first year. (SEC)
Gross margin fell to 74.8% in the third quarter from 76.6% a year earlier, and management expects a further sequential decline in the fourth quarter as longer, higher-cost Avance grafts make up more of sales. The acquired BioCircuit inventory could add further margin pressure in the near term. (The Motley Fool)
Axogen issued shares in January to repay debt and again in September to fund the BioCircuit purchase, increasing the share count and diluting existing owners. Further equity issuance could dilute shareholders again if the company needs more capital. (SEC)
Avance’s continued FDA approval depends on confirmatory studies verifying its clinical benefit for certain indications granted under the accelerated approval pathway. Unfavourable or delayed results could put a key product and future growth at risk. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Axogen Financial Performance
Revenues and expenses
Axogen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Axogen News
AllArticlesVideos
Funds containing Axogen
Fund name | Fund size | $AXGN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.28% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.28% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.28% |
iShares Ageing Population€AGED | $887M | 0.26% |
iShares Ageing Population£AGES | $887M | 0.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.